US generic drug pricing declined 4.1% YoY in March, showing stability compared to the 6% average deflation seen in FY25. FDA ANDA approvals remain healthy, tracking slightly above historical monthly averages.
Key Takeaways
- 1.Generic drug pricing declined 4.1% YoY in March, remaining stable and consistent with expectations of mid-high single-digit erosion.
- 2.ANDA approvals are tracking slightly above historical levels, with 87 approvals in March compared to the 78/month historical average.
- 3.The drug pricing basket methodology uses the top 500 generic drugs by IQVIA sales from 2014, representing approximately 95% of category sales at that time.
Table of Contents
- US generic drug pricing tracker: GRx deflation of 4% in March
- US generic drug pricing basket
- Disclosure Appendix
- Disclosures
- Regulatory disclosures
- Additional disclosures required under the laws and regulations of jurisdictions other than the United States
- Ratings, coverage universe and related definitions
- Global product; distributing entities
- General disclosures
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Matt Dellatorre, Ph.D.Salveen RichterElizabeth Webster, Ph.D.
Themes
Generic Price Erosion StabilityFDA Regulatory Velocity
Regions
North AmericaUnited States